These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31338174)

  • 1. Intranasal bevacizumab treatment on epistaxis in hereditary haemorrhagic telangiectasia: a case report.
    García-Martín E; Pernía-López S; Martínez-Ortega PA; Monje B; Ruiz-Martínez C; Sanjurjo-Saez M
    Eur J Hosp Pharm; 2019 Jul; 26(4):226-228. PubMed ID: 31338174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
    J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
    Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
    JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal Efudix reduces epistaxis in hereditary hemorrhagic telangiectasia.
    de Jel DVC; Disch FJM; Kroon S; Mager JJ; Verdam FJ
    Angiogenesis; 2020 Aug; 23(3):271-274. PubMed ID: 32112177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.
    Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C
    Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
    Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
    Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Life-threatening Anaemia in Patient with Hereditary Haemorrhagic Telangiectasia (Rendu-Osler-Weber Syndrome).
    Mikołajczyk-Solińska M; Leończyk K; Brzezina A; Rossa S; Kasznicki J
    Open Med (Wars); 2020; 15():134-138. PubMed ID: 32190736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial.
    Dupuis-Girod S; Ambrun A; Decullier E; Fargeton AE; Roux A; Bréant V; Colombet B; Rivière S; Cartier C; Lacombe P; Chinet T; Blivet S; Blondel JH; Gilbert-Dussardier B; Dufour X; Michel J; Harle JR; Dessi P; Faure F
    JAMA; 2016 Sep; 316(9):934-42. PubMed ID: 27599328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease.
    Guldmann R; Dupret A; Nivoix Y; Schultz P; Debry C
    Laryngoscope; 2012 May; 122(5):953-5. PubMed ID: 22447341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.
    Al-Samkari H; Kasthuri RS; Parambil JG; Albitar HA; Almodallal YA; Vázquez C; Serra MM; Dupuis-Girod S; Wilsen CB; McWilliams JP; Fountain EH; Gossage JR; Weiss CR; Latif MA; Issachar A; Mei-Zahav M; Meek ME; Conrad M; Rodriguez-Lopez J; Kuter DJ; Iyer VN
    Haematologica; 2021 Aug; 106(8):2161-2169. PubMed ID: 32675221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoscopic surgical treatment of epistaxis in hereditary haemorrhagic telangiectasia: our experience.
    Pagella F; Pusateri A; Maiorano E; Spinozzi G; Ugolini S; Lizzio R; Mirabella R; Tinelli C; Olivieri C; Matti E
    Acta Otorhinolaryngol Ital; 2021 Feb; 41(1):59-68. PubMed ID: 33746224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
    Dupuis-Girod S; Ambrun A; Decullier E; Samson G; Roux A; Fargeton AE; Rioufol C; Schwiertz V; Disant F; Chapuis F; Donazzolo Y; Paintaud G; Edery P; Faure F
    MAbs; 2014; 6(3):794-9. PubMed ID: 24481211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications from office sclerotherapy for epistaxis due to hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu).
    Hanks JE; Hunter D; Goding GS; Boyer HC
    Int Forum Allergy Rhinol; 2014 May; 4(5):422-7. PubMed ID: 24431220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients using pulsed dye laser and the effect of withholding treatment during the COVID pandemic.
    Jiang Y; Dennis SC; Brewin MP
    Lasers Med Sci; 2022 Oct; 37(8):3147-3153. PubMed ID: 35635649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Hereditary Haemorrhagic Telangiectasia with Bevacizumab - What More Needs to be Known?
    Morrissey E; Schmidt-Martin D; Buckley M
    Eur J Case Rep Intern Med; 2024; 11(1):004219. PubMed ID: 38223286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis.
    Sautter NB; Smith TL
    Otolaryngol Clin North Am; 2016 Jun; 49(3):639-54. PubMed ID: 27267016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia.
    Merlo CA; Yin LX; Hoag JB; Mitchell SE; Reh DD
    Int Forum Allergy Rhinol; 2014 Nov; 4(11):921-5. PubMed ID: 25145809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for Refractory Gastrointestinal Bleeding in Rendu-Osler-Weber Disease.
    Bernardes C; Santos S; Loureiro R; Borges V; Ramos G
    GE Port J Gastroenterol; 2018 Mar; 25(2):91-95. PubMed ID: 29662934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal closure for the treatment of epistaxis secondary to hereditary hemorrhagic telangiectasia.
    Sena Esteves S; Cardoso C; Silva A; Abrunhosa J; Almeida E Sousa C
    Acta Otorrinolaringol Esp; 2016; 67(6):345-348. PubMed ID: 27079134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.